BURNABY, BC, April 20 /CNW/ - Welichem Biotech Inc. (the "Company")
(TSX-V: WBI) announces the start of GLP toxicology studies for its lead,
anti-inflammatory drug WBI-1001. The long-term toxicology studies that are
currently underway are designed to support the filing of an Investigational
New Drug (IND) application for WBI-1001 with the U.S. FDA so as to initiate
Phase II/III clinical studies in the US. Welichem intends to submit an IND for
WBI-1001 in the Fall of 2009, following successful completion of the
Building on the successfully completed, 28 day clinical trials of the
non-steroid WBI-1001 cream on patients with chronic atopic dermatitis (AD) and
with psoriasis, plans are now progressing towards an international phase
II/III clinical program. The IND-enabling toxicological evaluation is part of
the program that is required as a prelude to the clinical trials.
WBI-1001 is a non-steroidal, anti-inflammatory drug candidate that has
been shown in prior clinical trials to be effective and to have good safety
profile. WBI-1001 is a novel, patented drug candidate that is being developed
by Welichem as a new treatment for AD, psoriasis and related diseases.
About Welichem Biotech Inc.
Welichem Biotech Inc. is a publicly-traded biotechnology company
developing therapeutic drugs in the fields of inflammatory diseases and
ON BEHALF OF THE BOARD
Tan Xiangdong, Chairman of the Board
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of the content of this news
release. This press release contains forward-looking statements that include
our belief as to the potential of our products. Certain risks and
uncertainties such as our ability to successfully commercialize the products
could cause the Company's actual results to differ materially from those in
the forward-looking statements.
For further information:
For further information: Genhui Chen, CEO, Tel.: (604) 432-1703, Email: